Faustino TorricoJoaquím GascónFabiana BarreiraBethania BlumIgor C. AlmeidaCristina Alonso‐VegaTayná BarbozaGraeme BilbeErika CorreiaWilson García2026-03-222026-03-22202110.1016/s1473-3099(20)30844-6https://doi.org/10.1016/s1473-3099(20)30844-6https://andeanlibrary.org/handle/123456789/43166Citaciones: 195For the Spanish translation of the abstract see Supplementary Materials section.enBenznidazoleMedicineDiscontinuationTolerabilityInternal medicineAdverse effectPopulationPlaceboNew regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trialarticle